Edgar Filing: Mirati Therapeutics, Inc. - Form 4

Mirati Therapeutics, Inc Form 4 May 23, 2014						
FORM 4 UNI Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	V ATEMENT OF CHA ed pursuant to Section n 17(a) of the Public	URITIES AND EXCHANGI Vashington, D.C. 20549 ANGES IN BENEFICIAL O SECURITIES n 16(a) of the Securities Excha Utility Holding Company Act Investment Company Act of	WNERSHIP OF ange Act of 1934, t of 1935 or Section	OMB APPROVAL OMB 3235-0287 Number: January 31, 2005 Estimated average burden hours per response 0.5		
(Print or Type Responses) 1. Name and Address of Rep Gergen Mark J	Symbo	suer Name and Ticker or Trading ol ti Therapeutics, Inc. [MRTX]	Issuer	Reporting Person(s) to k all applicable)		
(Last) (First) 9363 TOWNE CENTR DRIVE, SUITE 200	(Mont	e of Earliest Transaction h/Day/Year) 1/2014	Director 10% Owner Officer (give title Other (specify below) Exec. VP and COO			
(Street) SAN DIEGO, CA 9212	Filed(mendment, Date Original Month/Day/Year)	 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person 			
(City) (State)	(Zip) T	able I - Non-Derivative Securities A		or Beneficially Owned		
	a Date 2A. Deemed Year) Execution Date, is any (Month/Day/Year	3.4. SecuritiesfTransactionAcquired (A) orCodeDisposed of (D)	5. Amount of 6. Securities F Beneficially (I Owned (I Following (I Reported Transaction(s) (Instr. 3 and 4)	Ownership 7. Nature of orm: Direct Indirect D) or Indirect Beneficial		
Reminder: Report on a separ	ate line for each class of s	information con required to resp	or indirectly. spond to the collect tained in this form a bond unless the form ently valid OMB cont	n (9-02)		

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

Edgar Filing: Mirati Therapeutics, Inc. - Form 4

(Instr. 3)	Price of Derivative Security		(Mont	h/Day/Year)	(Instr. 8)	Acquired or Dispose (D) (Instr. 3, and 5)	sed of				
					Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	\$ 17.41	05/21/2014			А	50,000		<u>(1)</u>	05/20/2024	Common Stock	50,000
Report	ting Owr	ers									
Relationships											
Reporting Owner Name / Address			ector 1	0% Owner	Officer			Other			
SUITE 200	NE CENTRE I	ORIVE			Exec. V	P and CO	00				
Signat	ures										
/s/ Jamie A Attorney-in	A. Donadio, 1-Fact		0:	5/21/2014							

**Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Date

(1) 1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.